Lodoxamide

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Lodoxamide
Lodoxamide structure.png
Names
IUPAC name
2-[2-Chloro-5-cyano-3-(oxaloamino)anilino]-2-oxoacetic acid
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.237.246
UNII
Properties
C11H6ClN3O6
Molar mass 311.63 g·mol−1
Pharmacology
S01GX05 (WHO)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is ☑Y☒N ?)
Infobox references

Lodoxamide is an antiallergic pharmaceutical drug. It is marketed under the tradename Alomide in the UK. Like cromoglicic acid it acts as a mast cell stabilizer.[1] In 2014 lodoxamide and bufrolin were found to be potent agonists at the G protein-coupled receptor 35, an orphan receptor believed to play a role in inflammatory processes, pain and the development of stomach cancer.[2]

See also[edit]

References[edit]

  1. ^ Avunduk, A. M.; Avunduk, M. C.; Kapicioglu, Z.; Akyol, N.; Tavli, L. (2000). "Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis". Ophthalmology. 107 (7): 1333–1337. doi:10.1016/S0161-6420(00)00089-0. PMID 10890862.
  2. ^ MacKenzie, AE; Caltabiano, G; Kent, TC; Jenkins, L; McCallum, JE; Hudson, BD; Nicklin, SA; Fawcett, L; Markwick, R; Charlton, SJ; Milligan, G (2014). "The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35". Molecular Pharmacology. 85 (1): 91–104. doi:10.1124/mol.113.089482. ISSN 0026-895X. PMC 3868900. PMID 24113750.